Acadia Pharmaceuticals (ACAD) Q2 2026 earnings review
Outstanding Commercial Execution and a Massive Regulatory Win
Acadia delivered a stellar quarter, with total revenue surging 17% YoY (adjusted) to $308M, crushing previous quarterly plateaus. The growth engine is firing on all cylinders: DAYBUE net sales skyrocketed 30% to $125M, driven by the STIX formulation launch, and NUPLAZID broke out of its Q1 rut to hit $183M. Crucially, the massive dark cloud hovering over the stock—the European regulatory rejection of DAYBUE—has evaporated. The CHMP reversed its previous negative trend and adopted a positive opinion, clearing the path for European expansion. This flawless commercial quarter allowed management to raise full-year revenue guidance to $1.24B-$1.30B while lowering R&D expense expectations.
🐂 Bull Case
The new powder formulation is doing exactly what it was designed to do: driving restarts and initiating treatment-naive patients. Sequential growth of $24M from Q1 to Q2 proves the acceleration is real.
The CHMP's positive opinion for DAYBUE in Europe completely removes a major bearish overhang, validating the drug's efficacy profile and opening a lucrative new geography.
🐻 Bear Case
The entire pipeline narrative hinges on the Phase 2 remlifanserin readout for Alzheimer's disease psychosis in Sept-Oct. Placebo effects routinely ruin trials in this indication, making this a high-wire act.
Commercial execution is expensive. SG&A hit $160M this quarter, consuming over 50% of total revenue. Pushing drugs into the primary care community is heavily reliant on sheer sales force volume.
⚖️ Verdict: 🟢
Bullish. Acadia answered every commercial question this quarter. DAYBUE is re-accelerating, NUPLAZID is stable, and the surprise EU regulatory win de-risks the international strategy. The upcoming Phase 2 data remains a wild card, but the baseline business is highly profitable and throwing off cash.
Key Themes
Massive Reversal: EU Opens the Door for DAYBUE
The most significant fundamental shift this quarter isn't in the numbers, it's regulatory. After a negative trend vote in late 2025 forced Acadia into a risky re-examination process, the CHMP officially adopted a positive opinion for DAYBUE. If approved by the European Commission, it will become the first authorized treatment for Rett syndrome in the EU. This completely reverses a major concern from the last two quarters and significantly increases DAYBUE's peak sales potential.
DAYBUE STIX Formulation Ignites Growth
DAYBUE sales surged to $125M, a 30% YoY increase and a massive $24M sequential jump from Q1. This validates management's thesis that the new DAYBUE STIX powder formulation would reduce friction, re-engage the ~1,000 previously discontinued patients, and capture treatment-naive patients. This is textbook lifecycle management yielding immediate financial dividends.
NUPLAZID Sales Force Expansion Paying Off
After a concerning Q1 where NUPLAZID suffered from a 'refill lag' (generating only $167M), Q2 sales rebounded to $183M (+10% YoY adjusted). The 30% sales force expansion completed earlier this year is gaining traction in the field, successfully driving new-to-brand prescriptions and maximizing the return on their aggressive direct-to-consumer ad campaigns.
Trading Long-Term R&D for Short-Term Margins?
While profitability looks great, the guidance adjustments tell a specific story. Management lowered full-year R&D guidance by $30M (to $355-$380M) while keeping SG&A guidance sky-high at $660-$700M. The concern here is whether pipeline progression is quietly slipping or being deprioritized to fund the aggressive commercial rollout of NUPLAZID and DAYBUE.
The Remlifanserin Binary Event Approaches
The Phase 2 RADIANT study for remlifanserin in Alzheimer's disease psychosis (ADP) is slated for a September/October readout. Management has repeatedly touted this as a $4 billion peak sales opportunity. However, ADP trials are notoriously difficult to run, specifically regarding managing the placebo effect. This represents an enormous binary event that could radically alter the company's valuation in either direction.
Inflation Reduction Act (IRA) Noise Subsiding
In late 2025, a sudden non-recurring IRA rebate accrual change caused a $20M hit to net sales. This quarter, non-GAAP adjustments related to the IRA were minimal, suggesting the company has a better handle on modeling the financial impact of Medicare Part D redesigns and IRA caps.
Other KPIs
Combined R&D ($82M) and SG&A ($160M) hit $242M in Q2. Despite this heavy spend, total revenue of $308M easily covered it, yielding an operating income of $37.8M. This is a vast improvement from Q1 2026, where operating income was briefly negative due to front-loaded commercial investments.
Up heavily from $820M at the end of 2025 and $859M in Q1 2026. Acadia is now generating meaningful cash from operations, providing absolute security for pipeline funding and potential business development opportunities.
Guidance
Accelerating. Raised from the previous range of $1.22 - $1.28 billion. The midpoint of $1.27 billion implies a robust 18.5% YoY growth over FY25's $1.07 billion, proving the dual-franchise strategy is working.
Accelerating. Raised from $460 - $490 million. The midpoint ($495M) implies stellar 26.5% YoY growth versus FY25 ($391M). Management clearly expects the STIX formulation adoption to snowball in the second half of the year.
Stable. The guidance was reaffirmed, implying roughly 13% YoY growth. The lack of a raise here suggests management is waiting to see sustained pull-through from the sales force expansion before getting overly aggressive.
Decelerating. Lowered from the previous guidance of $385 - $410 million. This implies either clinical trial efficiencies, shifted timelines for earlier-stage assets, or a deliberate pivot to harvest cash flow.
Key Questions
R&D Spend Reduction
You lowered full-year R&D guidance by $30 million. Are any specific trial initiations being delayed, or is this purely operational efficiency?
EU Launch Economics
With the CHMP positive opinion secured, what is the expected commercial launch timeline for DAYBUE in Europe, and how should we model the gross-to-net and pricing dynamics compared to the US?
Remlifanserin Placebo Management
As we approach the Sept-Oct readout for Remlifanserin in ADP, what specific operational measures did you implement during the Phase 2 trial to mitigate the placebo effect that has plagued so many competitors in this space?
DAYBUE STIX Market Expansion
You previously estimated STIX could unlock 400 incremental patients over 2-3 years. Given the massive Q2 beat, are you tracking ahead of that timeline, and has your view on total addressable market penetration changed?